title: Tyrosine kinase inhibitors alter composition of nicotinic receptors on neurons.
abstract: Protein tyrosine kinase (PTK) inhibitors were used to examine the roles of tyrosine phosphorylation in synaptic function. We show here that two different PTK inhibitors, herbimycin A and lavendustin A, both selectively downregulate a subpopulation of nicotinic acetylcholine receptors (AChRs) on chick ciliary ganglion neurons in culture. The downregulation requires a number of hours to occur and involves only those receptors containing the alpha 3, alpha 5, and beta 4 gene products. Not affected are AchRs that additionally contain the beta 2 gene product or AchRs that are made up of the alpha 7 gene product. The downregulation preferentially targets receptors destined for the cell surface and has little effect on the large pool of intracellular receptors. The receptor loss is not additive with that seen in the presence of either cycloheximide or tunicamycin, two compounds that the block appearance of new receptors. The downregulation induced by herbimycin A in surface receptors is accompanied by a specific decrement in the amount of alpha 3 protein in the cells. The results indicate that PTKs, either by phosphorylating AChR gene products directly or by acting through intermediary proteins, regulate the size and composition of the AChR pool maintained on the cell surface. Receptor regulation by PTKs may provide a mechanism for long-term control of synaptic signaling between neurons.
authors.affiliation: Department of Biology, University of California, San Diego, La Jolla 92093, USA.
authors.forename: R C
authors.initials: RC
authors.lastname: Haselbeck
authors.forename: D K
authors.initials: DK
authors.lastname: Berg
mesh_terms: D000818:Animals; D016227:Benzoquinones; D002462:Cell Membrane / Q000378:metabolism; D002478:Cells, Cultured; D002642:Chick Embryo; D015536:Down-Regulation; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005726:Ganglia, Parasympathetic / Q000378:metabolism; D047029:Lactams, Macrocyclic; D009474:Neurons / Q000187:drug effects / Q000378:metabolism*; D010636:Phenols / Q000494:pharmacology*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011809:Quinones / Q000494:pharmacology*; D011978:Receptors, Nicotinic / Q000096:biosynthesis* / Q000187:drug effects / Q000378:metabolism; D017828:Rifabutin / Q000031:analogs & derivatives
chemical_list: D016227:Benzoquinones; D004791:Enzyme Inhibitors; D047029:Lactams, Macrocyclic; D010636:Phenols; D011809:Quinones; D011978:Receptors, Nicotinic; D017828:Rifabutin; C062898:lavendustin A; C020754:herbimycin; D011505:Protein-Tyrosine Kinases